Skip to main content
logo
Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
103.63
+1.78 (1.75%)
At close: Aug 14, 2026, 4:00 PM EDT
103.58
-0.05 (-0.05%)
After-hours: Aug 14, 2026, 7:34 PM EDT

Spyre Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---0.892.3318.74
Revenue Growth
----61.96%-87.57%-
Gross Profit
-215.8-171.65-162.79-83.16-56.25-38.33
Operating Income
-271.34-219.56-208.57-117.61-84.78-65.65
Net Income
-150.21-126.54-149.56-94.88-83.82-65.8
Earnings Per Share
-2.01-1.98-3.18-13.76-24.86-25.02
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,145756.53603.09339.2855.7193.13
Total Debt
----4.655.48
Net Cash (Debt)
1,145756.53603.09339.2851.0787.65
Net Cash Growth
117.51%25.44%77.76%564.39%-41.74%-37.73%
Net Cash Per Share
15.3311.8112.8249.1915.1533.33

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-208.94-169.25-157.41-99.91-80.14-53.72
Capital Expenditures
-----0.04-0.57
Free Cash Flow
-208.94-169.25-157.41-99.91-80.18-54.29
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------204.55%
Operating Margin
----13274.49%-3640.23%-350.33%
Pretax Margin
----38241.08%-3604.59%-350.39%
Profit Margin
----10709.14%-3598.76%-351.14%
FCF Margin
----11276.52%-3442.76%-289.71%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
---874.9111.8812.50